Research, Development, And Testing Services - Insider Trading Data

Insiders are officers, directors, or significant investors. This page shows insider sentiment and transactions for the Research, industry. Research shows that insider trades are predictive of future stock returns. By examining insider trades for an industry, we can understand what well-informed people think of the overall future industry prospects.

Research, Development, And Testing Services - Insider Buy/Sell Ratio

Insider selling and buying is a useful indicator for analyzing the market because it serves as a proxy for their optimism or pessimism in their own companies. By looking at ratio of total selling and buying across the entire market, we might be able to draw some conclusions about the future market.

We offer two charts here. The first one shows the total dollar volume of buying and selling by insiders. The second chart shows the ratio of the number of insiders selling, vs. the number of insiders buying. In both charts, we filter out trades made by indirect holders (such as trusts), and 10% owners (who, although considered an 'insider' by the SEC, do not actually manage the companies in which they are considered insiders).

Corporate Insider Buy Sell Ratio (Dollar Volume) - Research, Development, And Testing Services
Corporate Insider Buy Sell Ratio (Insider Count) - Research, Development, And Testing Services
Research, Development, And Testing Services - Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b5-1 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Security Form Insider Code 10b5-1 Direct Share
Price
Shares
Changed
2025-04-07 OABI / OmniAb, Inc. 4 GUSTAFSON KURT A S - Sale D 2 -7,206
2025-04-07 OABI / OmniAb, Inc. 4 Berkman Charles S S - Sale D 2 -7,206
2025-04-07 OABI / OmniAb, Inc. 4 FOEHR MATTHEW W M - Exercise D 36,458
2025-04-07 OABI / OmniAb, Inc. 4 Berkman Charles S M - Exercise D 13,542
2025-04-07 OABI / OmniAb, Inc. 4 GUSTAFSON KURT A M - Exercise D 13,542
2025-04-07 NRC / NRC Health 4 Monnich Andrew A - Award D 100,000
2025-04-07 NRC / NRC Health 4 Hrdy Helen A - Award D 100,000
2025-04-01 OABI / OmniAb, Inc. 4 GUSTAFSON KURT A S - Sale D 2.37 -11,963
2025-04-01 NOTV / Inotiv, Inc. 4 Coelho Mary Theresa S - Sale D 2.3483 -5,500
2025-04-01 OABI / OmniAb, Inc. 4 GUSTAFSON KURT A M - Exercise D 23,244
2025-04-01 INCY / Incyte Corporation 4 Iyengar Vijay K A - Award D 11,159
2025-04-01 INCY / Incyte Corporation 4 Stamoulis Christiana A - Award D 18,970
2025-04-01 INCY / Incyte Corporation 4 Stamoulis Christiana A - Award D 18,598
2025-04-01 INCY / Incyte Corporation 4 Flannelly Barry P A - Award D 14,976
2025-04-01 INCY / Incyte Corporation 4 Morrissey Michael James A - Award D 4,649
2025-04-01 INCY / Incyte Corporation 4 Hoppenot Herve A - Award D 66,899
2025-04-01 INCY / Incyte Corporation 4 Flannelly Barry P A - Award D 11,159
2025-04-01 INCY / Incyte Corporation 4 Iyengar Vijay K A - Award D 10,982
2025-04-01 INCY / Incyte Corporation 4 SWAIN PAULA J A - Award D 10,982
2025-04-01 INCY / Incyte Corporation 4 Stein Steven H A - Award D 37,198
2025-04-01 INCY / Incyte Corporation 4 Stein Steven H A - Award D 20,967
2025-04-01 INCY / Incyte Corporation 4 SWAIN PAULA J A - Award D 11,159
2025-03-31 MEDP / Medpace Holdings, Inc. 4 Kraft Robert O. M - Exercise D 57
2025-03-31 MEDP / Medpace Holdings, Inc. 4 Carley Brian T M - Exercise D 63
2025-03-31 MEDP / Medpace Holdings, Inc. 4 McCarthy Cornelius P. III M - Exercise D 50
2025-03-31 INCY / Incyte Corporation 4 HARRIGAN EDMUND A - Award D 60.55 363
2025-03-31 INCY / Incyte Corporation 4 BAKER BROS. ADVISORS LP See Footnotes A - Award I 487
2025-03-31 INCY / Incyte Corporation 4 BAKER BROS. ADVISORS LP See Footnotes A - Award I 487
2025-03-31 INCY / Incyte Corporation 4 Clancy Paul J A - Award D 60.55 358
2025-03-25 INCY / Incyte Corporation 4 Trotta Matteo F - Taxes D 62.08 -537
2025-03-21 OABI / OmniAb, Inc. 4 HIGGINS JOHN L P - Purchase D 2.28 4,000
2025-03-20 OABI / OmniAb, Inc. 4 HIGGINS JOHN L P - Purchase D 2.35 125,750
2025-03-18 MXCT / MaxCyte, Inc. 4 Swirsky Douglas J S - Sale D 3.1793 -6,939
2025-03-18 MXCT / MaxCyte, Inc. 4 Sandoval David I. S - Sale D 3.1793 -353
2025-03-18 MXCT / MaxCyte, Inc. 4 Soleymannezhad Ali S - Sale D 3.1793 -1,211
2025-03-14 INCY / Incyte Corporation 4 Flannelly Barry P S - Sale D 67.68 -19,147
2025-03-14 INCY / Incyte Corporation 4 Flannelly Barry P S - Sale D 67.85 -461
2025-03-14 INCY / Incyte Corporation 4 Flannelly Barry P S - Sale D 67.88 -199
2025-03-14 NOTV / Inotiv, Inc. 4 Neff R Matthew A - Award D 39,392
2025-03-14 NOTV / Inotiv, Inc. 4 Krupp Jeffrey Arthur A - Award D 25,000
2025-03-14 NOTV / Inotiv, Inc. 4 Freeman Jeffrey Brennan A - Award D 15,000
2025-03-14 NOTV / Inotiv, Inc. 4 Hardy Adrian A - Award D 25,000
2025-03-14 NOTV / Inotiv, Inc. 4 Taylor Beth A - Award D 40,000
2025-03-14 NOTV / Inotiv, Inc. 4 Beattie John Gregory A - Award D 25,000
2025-03-14 NOTV / Inotiv, Inc. 4 Coelho Mary Theresa A - Award D 39,392
2025-03-14 NOTV / Inotiv, Inc. 4 Sagartz John E A - Award D 30,000
2025-03-14 MXCT / MaxCyte, Inc. 4 Swirsky Douglas J A - Award D 37,500
2025-03-14 MXCT / MaxCyte, Inc. 4 Sandoval David I. A - Award D 23,125
2025-03-14 NOTV / Inotiv, Inc. 4 Harrington Michael J A - Award D 39,392
2025-03-14 NOTV / Inotiv, Inc. 4 Leasure Robert Jr. A - Award D 429,730
P
Åbent marked eller privat køb af ikke-afledte eller afledte værdipapirer
S
Åbent marked eller privat salg af ikke-afledte eller afledte værdipapirer
A
Tildeling, tildeling eller anden erhvervelse af værdipapirer fra virksomheden (såsom en option)
C
Konvertering af derivat
D
Salg eller overførsel af værdipapirer tilbage til virksomheden
F
Betaling af udnyttelseskurs eller skatteforpligtelse ved brug af en del af værdipapirer modtaget fra selskabet
G
Gave af værdipapirer af eller til insideren
K
Aktieswaps og lignende sikringstransaktioner
M
Udnyttelse eller konvertering af afledt værdipapir modtaget fra virksomheden (såsom en option)
V
En transaktion rapporteret frivilligt på formular 4
J
Andet (ledsaget af en fodnote, der beskriver transaktionen)